Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
10 November 2022 - 08:01AM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage
biopharmaceutical company focused on the development of novel
targeted therapeutics for Alzheimer’s disease, announced today that
management will participate in a fireside chat at the Stifel
Healthcare Conference on Wednesday, November 16,
2022 at 4:10 p.m. ET. The live webcast may be accessed
under the Investors tab on www.acumenpharm.com and will
be archived for 14 days.
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA,
with clinical operations based in Carmel, IN, is a clinical stage
biopharmaceutical company developing a novel disease-modifying
approach to treat Alzheimer’s disease. Acumen’s scientific founders
pioneered research on AβOs, which a growing body of evidence
indicates are primary triggers of Alzheimer’s disease pathology.
Acumen is currently focused on advancing its investigational
product candidate, ACU193, a humanized monoclonal antibody that
selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1
clinical trial involving early Alzheimer’s disease patients. For
more information, visit www.acumenpharm.com.
Investors: Alex Braunabraun@acumenpharm.com
Media: AcumenPR@westwicke.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Mar 2023 to Mar 2024